FMP

FMP

Enter

ENTA - Enanta Pharmaceutica...

photo-url-https://images.financialmodelingprep.com/symbol/ENTA.png

Enanta Pharmaceuticals, Inc.

ENTA

NASDAQ

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

6.65 USD

-0.18 (-2.71%)

ENTA Financial Statements

Quarter

2025 Q1

2024 Q4

2024 Q3

2024 Q2

Total Revenue

16.96M

14.61M

17.97M

17.05M

Cost of Revenue

0

0

0

621k

Gross Profit

16.96M

14.61M

17.97M

16.43M

Operating Expenses

40.5M

44.46M

42.16M

49.82M

Research and Development

27.66M

30.78M

28.74M

35.59M

Selling, General & Administrative Expenses

12.85M

13.68M

13.41M

14.23M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

12.85M

13.68M

13.41M

14.23M

Other Expenses

0

0

0

0

Operating Income

-23.54M

-29.85M

-24.18M

-32.77M

Total Other Income/Expenses Net

837k

668k

1.13M

1.25M

Income Before Tax

-22.71M

-29.19M

-23.05M

-31.52M

Income Tax

-416k

-363k

-395k

-363k

Net Income

-22.29M

-28.82M

-22.66M

-31.16M

Basic EPS

-1.05

0

-1.07

-1.47

EPS Diluted

-1.05

0

-1.07

-1.47

Basic Average Shares

21.24M

0

21.18M

21.17M

Diluted Average Shares

21.24M

0

21.18M

21.17M

EBITDA

-19.86M

-26.13M

-20.1M

-28.34M

Retained Earning Schedule

Quarter

2025 Q1

2024 Q4

2024 Q3

2024 Q2

Retained Earnings (Previous Year)

-323.04M

-294.22M

-271.56M

-240.4M

Net Income

-22.29M

-28.82M

-22.66M

-31.16M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-345.33M

-323.04M

-294.22M

-271.56M

Other Distributions

-22.29M

-28.82M

-22.66M

-31.16M

PPE Schedule

Quarter

2025 Q1

2024 Q4

2024 Q3

2024 Q2

Gross PPE

77.04M

73.35M

66.26M

58.37M

Annual Depreciation

889k

479k

594k

621k

Capital Expenditure

-8.74M

-8.95M

-6.54M

-1.67M

Net PPE

84.9M

81.82M

72.21M

59.42M

Intangible and Goodwill Schedule

Quarter

2025 Q1

2024 Q4

2024 Q3

2024 Q2

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep